Santen Pharmaceutical has developed a monoclonal antibody with high affinity for VEGF, crucial for treating eye diseases. The antibody binds to VEGF with a dissociation constant of 1×10-11 mol/L or less, offering potential advancements in medical treatment. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Santen Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Monoclonal antibody with high affinity for vegf

Source: United States Patent and Trademark Office (USPTO). Credit: Santen Pharmaceutical Co Ltd

A recently granted patent (Publication Number: US11872271B2) discloses a monoclonal antibody against Vascular Endothelial Growth Factor (VEGF) and its antigen-binding fragment. The antibody is designed with specific amino acid sequences in its complementarity-determining regions (CDRs) to bind to VEGF and inhibit its interaction with VEGF receptors, VEGFR1 and VEGFR2. The patent covers variations of the antibody, including chimeric, humanized, and caninized forms, with constant regions derived from human or canine IgG1 antibodies.

Moreover, the patent includes claims for a hybridoma that produces the monoclonal antibody, a pharmaceutical composition containing the antibody, and a kit for research purposes. The patent also outlines a method for treating VEGF-mediated cancers and eye diseases by administering the antibody to inhibit angiogenesis or vascular hyperpermeability. The cancers mentioned in the patent range from colorectal cancer to melanoma, while the VEGF-mediated eye diseases include conditions like age-related macular degeneration and diabetic retinopathy. The antibody is designed to bind to VEGF with high affinity, with a dissociation constant of 1×10-11 mol/L or less, making it a promising candidate for therapeutic applications in oncology and ophthalmology.

To know more about GlobalData’s detailed insights on Santen Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies